```html

Yardley’s Disease (Hypersensitivity Pneumonitis)

Overview

Yardley’s disease is an older eponym for hypersensitivity pneumonitis (HP), an immune‑mediated inflammatory lung disorder that occurs after repeated inhalation of a wide variety of organic or chemical antigens. The condition is sometimes called “farmer’s lung,” “bird‑fancier’s lung,” or “humidifier lung” depending on the source of the antigen.

• Who it affects: Anyone exposed to the offending antigen can develop HP, but most cases occur in adults aged 30‑70 years who work or live in environments with high antigen loads (e.g., farmers, bird owners, bakers, metal workers, home‑owners using contaminated humidifiers).
• Prevalence: In the United States, HP is estimated to affect approximately 1–2 per 100,000 people annually. The true prevalence is likely higher because mild cases are under‑diagnosed.
• Geographic variation: Higher rates are reported in agricultural regions of Europe, North America, and parts of Asia where exposure to moldy hay, grain, or animal droppings is common.

Symptoms

Symptoms can appear within minutes to several weeks after exposure and may be acute, sub‑acute, or chronic. The pattern often mirrors the intensity and duration of antigen contact.

Acute (< hours‑days)

• Fever & chills – usually low‑grade (37.5‑38.5 °C).
• Dry cough – non‑productive, may be persistent.
• Shortness of breath (dyspnea) – especially on exertion.
• Chest tightness or pleuritic pain.
• Fatigue & malaise.
• Wheezing – less common than in asthma.

Sub‑Acute (weeks‑months of repeated exposure)

• Persistent dry cough.
• Gradual worsening of dyspnea on exertion.
• Low‑grade fever or night sweats.
• Weight loss.
• Fine inspiratory crackles heard on auscultation.

Chronic (months‑years)

• Progressive shortness of breath, even at rest.
• Chronic dry cough.
• Clubbing of fingertips (in advanced cases).
• Exercise intolerance.
• Symptoms of right‑sided heart failure (edema, abdominal swelling) if pulmonary hypertension develops.

Because symptoms mimic common respiratory infections, HP is frequently misdiagnosed as asthma, COPD, or viral bronchitis.

Causes and Risk Factors

HP results from a type III (immune‑complex) and type IV (cell‑mediated) hypersensitivity reaction to inhaled antigens.

Common Antigen Sources

• Thermophilic actinomycetes in moldy hay, grain, or straw – “farmer’s lung.”
• Bird proteins (feathers, droppings) – “bird‑fancier’s lung.”
• Molds & fungi in humidifiers, air‑conditioners, hot tubs – “humidifier lung.”
• Penicillium, Aspergillus, and other spores in indoor environments.
• Organic dusts from cotton, coffee, tea, or flour – “baker’s lung.”
• Chemical agents such as isocyanates, metalworking fluids, or certain pesticides.

Risk Factors

• Occupational exposure: farming, poultry work, woodwork, animal handling, metal‑working, or bakery jobs.
• Hobbies that involve birds, aquarium maintenance, or indoor gardening.
• Living in damp, poorly ventilated homes.
• Genetic predisposition: certain HLA‑DR alleles (e.g., HLA‑DRB1*13) have been linked to increased susceptibility.
• Smoking does not protect against HP and may worsen outcomes, especially in chronic disease.
• Pre‑existing lung disease (asthma, COPD) can mask or compound symptoms.

Diagnosis

Diagnosing HP requires a combination of clinical history, imaging, pulmonary function testing, and sometimes lung biopsy. No single test is definitive.

1. Detailed Exposure History

• Identify potential antigen sources at work, home, or during hobbies.
• Note timing of symptom onset relative to exposure.

2. Physical Examination

• Inspiratory crackles (fine “Velcro” sounds) are typical.
• Digital clubbing may be present in chronic disease.

3. Pulmonary Function Tests (PFTs)

• Restrictive pattern: Decreased total lung capacity (TLC) and forced vital capacity (FVC).
• Reduced diffusing capacity (DLCO): Often the earliest abnormality.
• Obstructive changes can coexist if asthma or COPD is present.

4. Imaging

• Chest X‑ray: May show diffuse interstitial infiltrates, but is less sensitive.
• High‑resolution computed tomography (HRCT): Modality of choice.
  • Acute/sub‑acute: Ground‑glass opacities, centrilobular nodules, mosaic attenuation.
  • Chronic: Reticulation, honey‑comb cystic changes, traction bronchiectasis.

5. Laboratory Tests

• Complete blood count – may show mild leukocytosis.
• Serum precipitating antibodies (IgG) against specific antigens (enzyme‑linked immunosorbent assay, ELISA). Positive tests support exposure but are not diagnostic alone.

6. Bronchoscopy & BAL (Bronchoalveolar Lavage)

• Elevated lymphocyte percentage (>20–30%) is characteristic.
• Helps rule out infection and sarcoidosis.

7. Lung Biopsy (when uncertain)

• Transbronchial or surgical (VATS) biopsy may reveal poorly formed non‑caseating granulomas, interstitial lymphocytic infiltrates, and fibroblastic foci.

Diagnosis is usually confirmed when (1) there is a compatible exposure history, (2) imaging and PFT findings are consistent, and (3) there is improvement after antigen removal.

Treatment Options

Treatment focuses on (1) eliminating exposure, (2) controlling inflammation, and (3) managing chronic lung changes.

1. Antigen Avoidance

• Identify and eliminate the offending source (e.g., change bedding, clean humidifiers, avoid bird cages).
• Use personal protective equipment (PPE) such as N95 masks when exposure cannot be avoided.
• Improve home ventilation and control indoor humidity (< 50 %).

2. Pharmacologic Therapy

• Corticosteroids – First‑line for acute and sub‑acute HP.
  • Prednisone 0.5–1 mg/kg/day for 2‑4 weeks, then taper based on symptom and PFT improvement.
  • Long‑term low‑dose steroids may be needed in chronic disease, but risk of side effects must be weighed.
• Steroid‑sparing agents – Considered for steroid‑dependent or refractory cases.
  • Azathioprine 1.5–2 mg/kg/day.
  • Mycophenolate mofetil 1–1.5 g twice daily.
  • Rituximab in severe, refractory disease (limited evidence).
• Bronchodilators – Short‑acting beta‑agonists for symptomatic relief if wheeze is present.

3. Supportive Measures

• supplemental oxygen for resting hypoxemia (PaO₂ < 55 mmHg) or during exertion.
• Pulmonary rehabilitation programs improve exercise tolerance and quality of life.
• Immunizations – annual influenza and COVID‑19 vaccines, pneumococcal vaccination (PCV20/PPV23) per CDC guidelines.

4. Management of Complications

• Pulmonary hypertension: evaluated with echocardiography; treated with endothelin‑receptor antagonists or phosphodiesterase‑5 inhibitors if indicated.
• Fibrotic “end‑stage” disease: referral for lung transplantation evaluation when DLCO < 30% predicted and progressive despite therapy.

Living with Yardley’s Disease (Hypersensitivity Pneumonitis)

While there is no cure, many patients achieve good control with avoidance and medication. Below are practical strategies for daily life.

Environmental Control

• Keep indoor humidity between 30‑50 % using dehumidifiers.
• Clean or replace HVAC filters monthly; use high‑efficiency (HEPA) filters where possible.
• Regularly clean and disinfect humidifiers, air‑conditioners, and vaporizers.
• If you keep birds, maintain a separate, well‑ventilated area and clean cages daily; consider wearing a mask during cleaning.

Medication Adherence

• Use a pill organizer or smartphone reminders.
• Schedule regular follow‑up appointments for PFTs and imaging (every 6‑12 months).
• Report new side effects promptly (weight gain, mood changes, glucose intolerance from steroids).

Exercise & Pulmonary Rehab

• Start with low‑impact activities (walking, stationary cycling) and gradually increase intensity under professional guidance.
• Breathing techniques such as pursed‑lip breathing can reduce dyspnea during exertion.

Nutrition

• Maintain a balanced diet rich in antioxidants (fruits, vegetables) to support lung health.
• If on long‑term steroids, monitor calcium and vitamin D intake; discuss supplementation with your physician.

Psychosocial Support

• Join patient support groups (e.g., American Lung Association “HP Community”).
• Consider counseling if anxiety or depression arise from chronic illness.

Prevention

Because HP is triggered by identifiable environmental agents, prevention is largely about exposure control.

• Educate at‑risk workers on safe handling of organic dusts—use respirators, wet‑cleaning methods, and proper storage.
• Implement routine workplace inspections for mold or fungal growth.
• Homeowners: avoid indoor plants in poorly ventilated rooms, clean mold promptly, and replace water‑filled humidifiers weekly.
• Regular veterinary check‑ups for birds; keep bird‑cage sand and droppings sealed.

Complications

If HP is not identified early or exposure continues, irreversible lung damage may occur.

• Progressive fibrosis – leads to a restrictive lung pattern and chronic respiratory insufficiency.
• Pulmonary hypertension – increased pressure in pulmonary arteries, causing right‑heart strain.
• Respiratory failure – may require long‑term oxygen therapy or mechanical ventilation.
• Secondary infections – chronic inflammation and steroid use raise pneumonia risk.
• Reduced quality of life and functional capacity – limitations in work, exercise, and daily activities.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Heart, Lung, and Blood Institute (NHLBI), American Thoracic Society, European Respiratory Society, peer‑reviewed articles in The Lancet Respiratory Medicine and Chest (2022‑2024). All information is for educational purposes and does not replace professional medical advice.

```